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SObjectives: Blood transfusion has been shown to have deleterious effect on lung cancer survival, but little data
are available that assess whether leukocyte-depleted (LD) blood has a similar adverse effect. Our institution has
been using LD red cells since 2001. We sought to determine whether LD blood has an effect on survival after
resection of early-stage lung cancer.
Methods: From a prospective database, we evaluated all patients with pathologic stage I non–small cell lung
cancer. Patients receiving LD blood were compared with those receiving no transfusion. Survival was estimated
using the Kaplan-Meier method and compared using the log–rank test. Multivariate analysis by Cox regression
was used to identify independent risk factors affecting survival.
Results: From 2001 to 2009, 361 patients were evaluated; 63 received LD red cell cell transfusion and 298 re-
ceived no transfusion. Median follow-up was 48 months. Disease-free survival (P<.001) and overall survival
(P<.001) were worse in patients receiving LD blood. Stratifying for stage, disease-free survival continued to be
worse with transfusion for stage IA (P ¼ .002) and IB (P ¼ .002). Similarly, overall survival continued to be
worse with transfusion for stage IA (P<.001) and IB (P<.001). For disease-free and overall survival, univariate
analysis revealed increased age, male gender, anemia, transfusion, and higher stage to be adverse factors, with
transfusion and higher stage continuing to be significant adverse factors after multivariate analysis.
Conclusions: Our data suggest that transfusion of LD blood is associated with a worse disease-free and overall
survival in patients with resected stage I non–small cell lung cancer. (J Thorac Cardiovasc Surg 2012;143:815-9)Much has been written regarding the potential harm of
blood transfusion to the anemic surgical oncology patient.
This effect is thought to be due in part to transfusion-
related immune modulation from leukocytes in allogeneic
donor blood. It was first demonstrated in the transplant pop-
ulation, with better allograft survival observed when the re-
cipient had a history of transfusion, implying transfusion
led to a downregulation of the host immune response to
the transplanted organ.1 It was postulated that transfusion-
related immunemodulation could similarly affect outcomes
from oncologic procedures, leading to increased local re-
currence and decreased survival.1,2 To avoid the potential
immunologic side effects of transfusion, many have
turned to leukocyte-depleted (LD) blood when transfusion
is necessary, citing potential advantages of fewer febrile
transfusion reactions, less alloimmunization, less
transfusion-associated graft-versus-host disease, less virale Department of Surgery,a The Warren Alpert Medical School of Brown Uni-
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The Journal of Thoracic and Catransmission (such as cytomegalovirus, Epstein-Barr virus,
and human immunodeficiency virus), and lower risk of can-
cer recurrence.2
Perioperative blood transfusion has been studied in lung
cancer with some authors showing a deleterious effect on
survival3-8 whereas others have not.9-13 Many of these
studies, however, involve a heterogeneous group of
patients in terms of stage and extent of resection. In
addition, there are no published reports evaluating the
affects of LD blood on lung cancer survival. The aim of
our study was to determine whether transfusion of LD
blood affected disease-free and overall survival in a uniform
group of patients with stage I non–small cell lung cancer re-
sected by lobectomy.
METHODS
From a prospective database, we evaluated all patients with pathologic
stage I non–small cell lung cancer resected by lobectomy. Patients under-
going sublobar resection, sleeve lobectomy, or pneumonectomy and pa-
tients receiving preoperative or postoperative chemotherapy were
excluded. Staging positron emission tomography and mediastinoscopy
were routinely performed before pulmonary resection. During lobectomy,
mediastinal lymph node sampling was performed. All surgical procedures
were performed by a single surgeon (T.N.). Patients who received allogenic
LD red cells (in-hospital or within 30 days of surgery) were compared with
those who received no transfusion. Leukocyte reduction of red cells was
performed before storage using either a whole blood in-line filter (Sepacell
RZ2000; Fenwal, Deerfield, Ill) or a red cell in-line filter (RCM1 filter;
PALL Medical, Covina, Calif). These filters consistently manufacture
leukocyte-reduced red cell concentrates that meet the Food and Drugrdiovascular Surgery c Volume 143, Number 4 815
TABLE 1. Patient characteristics
Characteristic
Transfusion*
(n ¼ 63)
No transfusion
(n ¼ 298)
P
value
Age years (percentile) 74 (66,78) 67 (60,75) <.001
Age>70 y 40 (63.5%) 115 (38.6%) <.001
Male 31 (49.2%) 130 (43.6%) .418
Hemoglobin g/dL
(percentile)
12.6 (11.5, 13.9) 13.5 (12.5, 14.4) .001
FEV1 L (percentile) 1.85 (1.47, 2.18) 2.07 (1.64, 2.45)y .029
Percent predicted FEV1
(percentile)
82 (64, 95) 84 (70, 99)y .333
Percent predicted
FEV1<60%
12 (19.0%) 36 (12.1%)y .142
Percent predicted DLCO
(percentile)
70 (55,84)z 79 (64,92)x .008
Percent predicted
DLCO<60%
21 (35.0%)z 50 (17.4%)x .002
EBL, mL (percentile) 250 (100, 500) 100 (50, 200) <.001
No. N2/N3 stations sampled
(percentile)
3 (3, 4) 3 (2, 4) .337
No. N2/N3 stations sampled
(count)
1 5 (7.9%) 30 (10.1%) .590
Abbreviation and Acronym
LD ¼ leukocyte-depleted
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6 leukocytes per unit.
Since 2001, only LD blood has been used for transfusion at our institution.
In this study, there were no set criteria to trigger transfusion. The decision
to transfuse was at the discretion of the physician.
Patient follow-up was performed every 4 months for the first 2 years,
then every 6 months from years 3 to 5, then yearly thereafter. Time zero
was defined as the time of surgery. First radiographic evidence of recurrent
disease was used to define the time to recurrence. Pathologic confirmation
of recurrent disease was not mandatory in cases in which the clinical and
radiographic evaluation was clearly consistent with recurrence. Recurrent
disease was categorized as local if recurrence was found at the surgical
margins, regional if recurrence was within the ipsilateral thoracic cavity,
mediastinum, or supraclavicular region, and distant if recurrencewas found
outside the local and regional zones. Death events were confirmed using the
Social Security Death Index. Patients alive and without recurrent disease
were censored at the time of their last known follow-up.
Primary outcomes of our study were disease-free and overall survival.
Disease-free survival was defined as the time from surgery to first disease
recurrence. Overall survival was defined as the time from surgery to death.
Mortality was defined as any death occurring in-hospital or within 30 days
of surgery. Staging of the patient’s disease was according to the American
Joint Commission for Cancer, seventh edition, staging for lung cancer, with
stage I being divided into IA (tumor size 3 cm and without visceral pleu-
ral invasion) and IB (tumor size>3 cm and 5 cm but 2 cm away from
the main carina, or tumor 5 cm that invades the visceral pleura or causes
atelectasis not involving the entire lung).14
Continuous variables were reported as median with 25th and 75th per-
centiles and compared using the Mann-Whitney U test. Categorical vari-
ables were reported as count with the corresponding proportion and
compared using the c2 or Fisher’s exact test. Survival was estimated using
the Kaplan-Meier method and compared using the log–rank test. Multivar-
iate analysis by Cox regression was used to identify independent risk fac-
tors for disease-free and overall survival, entering variables with a P value
of< .10 found at univariate analysis. All tests were 2-tailed. The statistic
software SPSS 19.0 for Windows (SPSS, Inc, Chicago, Ill) was used for
data analysis. Our institutional review board approved this study and
waived consent inasmuch as this study was a retrospective review of data
from our prospective database and the treatment received by all patients
represented the standard of care.2 6 (9.5%) 48 (16.1%)
3 26 (41.3%) 103 (34.6%)
4 16 (25.4%) 79 (26.5%)
5 10 (15.9%) 38 (12.8%)
Tumor size cm (percentile) 3.0 (1.5, 3.3) 2.2 (1.5, 3.0) .481
Cell type
Adenocarcinoma 43 (68.3%) 187 (62.8%) .514
Squamous cell 12 (19.0%) 69 (23.2%)
Large cell 6 (9.5%) 21 (7.0%)
Bronchoalveolar 2 (3.2%) 21 (7.0%)
Stage
IA 29 (46.0%) 170 (57.0%) .110
IB 34 (54.0%) 128 (43.0%)
Percentile, Indicates 25th and 75th percentiles; FEV1, forced expiratory volume in 1
second; DLCO, diffusion capacity of lung for carbon monoxide; EBL, estimated
blood loss. *Transfusion of leukocyte-depleted packed red blood cells. yFEV1 not
measured in 1 patient. zDLCO not measured in 3 patients. xDLCO not measured in
10 patients.RESULTS
From September 2001 to December 2009, 361 patients
underwent resection for pathologic stage I non–small cell
lung cancer by lobectomy. Survival was analyzed in 361 pa-
tients, 63 (17%) who received LD blood transfusions and
298 (83%) who did not receive a transfusion. No patients
in this study received platelet, fresh frozen plasma, or autol-
ogous blood transfusions. Median follow-up time was 48
months.
Comparison between the 2 groups is shown in Table 1.
The transfusion group was older, had a lower preoperative
hemoglobin level, a lower percent predicted diffusion ca-
pacity of lung for carbon monoxide, and a greater operative
blood loss. For the transfusion group, the median816 The Journal of Thoracic and Cardiovascular Surghemoglobin level at the time of transfusion was 8.2 g/dL
(range, 6.0-10.0 g/dL) and the median number of units
transfused was 2 (range, 1-7). Indications for transfusion in-
cluded return to the operating room for bleeding in 4 pa-
tients and symptomatic anemia in the other 59 patients.
Comparison of postoperative complications between the 2
groups is given in Table 2. The incidence of postoperative
bleeding and postoperative death were higher in the transfu-
sion group; with both complications not directly due to the
blood transfusion itself.
Of the 17 patients in the transfusion group with recur-
rence, 10 had pathologic confirmation and recurrences
were local in 2, regional in 7, and distant in 8. Of the 30 pa-
tients in the no transfusion group with recurrence, 18 had
pathologic confirmation and recurrences were local in 3,ery c April 2012
TABLE 2. Postoperative complications
Complication
Transfusion*
(n ¼ 63)
No transfusion
(n ¼ 298)
P
value
Atrial fibrillation 7 (11.1%) 22 (7.4%) .323
Bleeding (return to operating
room)
4 (6.3%) 0 .001
Pneumonia 3 (4.8%) 6 (2.0%) .195
Atelectasis requiring
bronchoscopy
2 (3.2%) 8 (2.7%) .235
Urinary tract infection 2 (3.2%) 2 (0.7%) .142
Empyema 2 (3.2%) 3 (1.0%) .211
Ileus 1 (1.6%) 1 (0.3%) .319
Myocardial infarction 1 (1.6%) 0 .175
Gastrointestinal bleed 1 (1.6%) 0 .175
Prolonged air leak (>7 days) 0 14 (4.7%) .142
Chylothorax 0 2 (0.7%) 1.000
Alcohol withdrawal 0 2 (0.7%) 1.000
Cerebral vascular accident 0 2 (0.7%) 1.000
Wound infection 0 1 (0.3%) 1.000
Perforated cecum 0 1 (0.3%) 1.000
Clostridium difficile 0 1 (0.3%) 1.000
Renal failure requiring dialysis 0 1 (0.3%) 1.000
Postoperative mortality 3 (4.8%)y 2 (0.7%)z .039
Patient with any complication 24 (38.1%) 60 (20.1%) .002
*Transfusion of leukocyte-depleted packed red blood cells. yDeath from pneumonia
in 2 and myocardial infarction in 1. zDeath from pneumonia and cerebral vascular
accident.
TABLE 3. Risk factors for survival, univariate analysis
Characteristic
Five-year
DFS
P value
DFS*
Five-year
OS
P value
OS*
Age
>70 79.2% .771 65.8% .001
70 83.3% 83.4%
Gender
Male 74.8% .014 66.9% .001
Female 87.6% 83.6%
Anemiay
Yes 73.9% .025 63.6% .027
No 84.3% 80.1%
Percent predicted FEV1
<60% 70.3% .158 66.1% .289
60% 83.9% 77.4%
Percent predicted DLCO
<60% 80.4% .897 73.1% .648
60% 81.9% 76.7%
No. N2/N3 stations sampled
4 81.6% .760 75.8% .654
<4 80.2% 74.5%
Transfusionz
Yes 58.0% <.001 53.5% <.001
No 86.8% 81.1%
Stage
IA 90.3% <.001 87.7% <.001
IB 70.7% 62.0%
DFS,Disease-free survival;OS, overall survival; FEV1, forced expiratory volume in 1
second; DLCO, diffusion capacity of lung for carbon monoxide. *Survival estimated
by Kaplan Meier method, compared using log–rank test. yWorld Health Organization
definition: male hemoglobin<13 g/dL; female hemoglobin<12 g/dL. zTransfusion
of leukocyte-depleted packed red blood cells.
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the pattern of recurrence between the 2 groups (P ¼ .817).
Univariate analysis for factors affecting disease-free and
overall survival is shown in Table 3. Male gender, preoper-
ative anemia, LD blood transfusion, and higher stage were
adverse factors for disease-free survival whereas older
age, male gender, preoperative anemia, LD blood transfu-
sion, and higher stage were adverse factors for overall sur-
vival. With multivariate analysis, only LD blood transfusion
and higher stage remained adverse risk factors for freedom
from disease, whereas male gender, LD blood transfusion,
and higher stage remained adverse risk factors for overall
survival (Table 4). Stratifying for stage, the negative effect
of LD blood transfusion on disease-free and overall survival
is illustrated in Figure 1 for stage IA and Figure 2 for
stage IB.DISCUSSION
There are conflicting data within the literature regarding
the effect of blood transfusion on lung cancer recurrence
and survival. However, many of the studies that show no ad-
verse effects of blood transfusion evaluate a heterogeneous
group of patients, including patients with various extents of
resection and stages of disease. In regard to the heterogene-
ity in the extent of resection, sublobar resection in tumor
size greater than 2 cm in a good surgical candidate is likely
suboptimal, and until the result of the ongoing randomizedThe Journal of Thoracic and CaCancer and Leukemia Group B 140503 trial is known, it re-
mains unknown whether sublobar resection is appropriate
for tumors sized 2 cm or less. The Lung Cancer Study
Group published the only randomized trial evaluating
lobectomy versus sublobar resection for T1 N0 (3 cm) tu-
mors, finding a worse recurrence-free survival and overall
survival (1-sided test determined a priori) when sublobar re-
section was performed.15 Because wedge resection is un-
likely to result in blood transfusion, transfusion trials that
include sublobar resection may result in a bias toward worse
survival for the nontransfused group. In regard to the hetero-
geneity in the stage of disease, owing to the poor baseline
survival in patients with advanced stage lung cancer, the ad-
verse affects of blood transfusion may not be evident in tri-
als that include these patients.
Studies with a more homogeneous group of patients,
evaluating those with stage I disease only, overwhelmingly
show worse survival in patients receiving blood transfu-
sion.3,5,7,8 In a prospective study by Nosotti and
associates,7 evaluating a well-defined group of patients
with stage I disease undergoing lobectomy (excluding sub-
lobar resection), blood transfusion resulted in decreased
disease-free and overall survival. Inasmuch as randomizedrdiovascular Surgery c Volume 143, Number 4 817
TABLE 4. Adverse risk factor for survival; multivariate analysis by Cox regression
Characteristic P value DFS Odds ratio DFS (95% CI) P value OS Odds ratio OS (95% CI)
Age>70 y — — .067 1.58 (0.97-2.58)
Anemia* .100 1.64 (0.91-2.96) .243 1.34 (0.82-2.17)
Gender, male .079 1.71 (0.94-3.10) .018 1.18 (1.10-2.94)
Transfusiony .003 2.46 (1.35-4.48) .001 2.26 (1.37-3.72)
Stage (IB) .001 2.90 (1.51-5.56) <.001 3.04 (1.76-5.26)
DFS, Disease-free survival; CI, confidence interval; OS, overall survival. *World Health Organization definition: male hemoglobin<13 g/dL; female hemoglobin<12 g/dL.
yTransfusion of leukocyte-depleted packed red blood cells.
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colleagues7 represents the strongest evidence currently
available given its prospective nature and the homogeneous
group of patients that was evaluated. However, no trial has
assessed whether LD blood transfusion similarly affects
lung cancer survival, which is the objective of our current
study. As discussed in the introduction, leukocytes in trans-
fused blood have been implicated in transfusion-related im-
mune modulation, which in turn may increase the risk of
cancer recurrence. Our study indicates that transfusion of
LD blood is associated with worse disease-free and overall
survival. It would seem that the negative effect of blood
transfusion on lung cancer survival is not solely due to leu-
kocytes and that other factors in blood, currently not known,
are involved.
The relationship between LD red cell transfusion and
cancer survival has been explored in gastrointestinal malig-
nant diseases, particularly in patients undergoing resection
for colon cancer. Randomized trials by van de Watering,16
Jensen,17 Skanberg,18 Lange,19 and their associates, com-
paring LD blood versus non-LD blood, showed no onco-
logic advantage to LD blood inasmuch as recurrence-freeFIGURE 1. Effect of leukocyte-depleted red cell transfusion for stage IA stra
95% confidence intervals.
818 The Journal of Thoracic and Cardiovascular Surgand overall survival were not different. These trials also per-
formed nonrandomized comparisons between the trans-
fused group (LD and non-LD blood) versus the
nontransfused group, finding worse survival outcomes in
patients receiving transfusion. These results are in agree-
ment with the results from our study and carry significant
implications for clinical practice. Blood transfusion, even
of LD blood, should be avoided whenever possible. A
high threshold for transfusion should be maintained. Metic-
ulous hemostasis during each step of pulmonary resection
becomes even more important from an oncologic perspec-
tive. The result of this study has led to changes in our
own clinical practice. Since 2009, when the data of this
study matured, our transfusion requirement in patients un-
dergoing major pulmonary resection has decreased to
10% (18/174), which compares favorably with the transfu-
sion requirement of 17% seen in this current study.
The strength of our study lies in the uniform group of pa-
tients evaluated (stage I, lobectomy only, surgery performed
by a single surgeon), the use of the new seventh edition stag-
ing system, and the long duration of follow-up. Our study
does have several limitations. First, this is a retrospectivetum. A, Disease-free survival. B, Overall survival. Vertical lines represent
ery c April 2012
FIGURE 2. Effect of leukocyte-depleted red cell transfusion for stage IB stratum. A, Disease-free survival. B, Overall survival. Vertical lines represent
95% confidence intervals.
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there may be other factors we did not control for that can
affect survival. Also, data regarding the time to recurrence
and the existence of recurrence in a patient who has died
is less accurate in retrospective studies. However, a random-
ized trial would not be ethical inasmuch as it would be un-
acceptable to administer a transfusion without a clinical
indication or to withhold transfusion from a patient who
needed blood. Although retrospectively analyzed, our data
are collected prospectively, which allows for a more accu-
rate data set than data acquired retrospectively. Second,
the number of patients in our study is small. The small num-
ber did not allow for more detailed analysis, such as the ef-
fect of increasing number of units transfused on lung cancer
survival. However, despite the small number of patients,
owing to the large difference in survival, our data strongly
suggest a negative effect on lung cancer survival with LD
blood transfusion.References
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